XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating Activities:    
Net income (loss) attributable to common stockholders $ (9,145) $ 38,558
Net income (loss) attributable to non-controlling interests 6,588 4,477
Net income (loss) (2,557) 43,035
Adjustments to reconcile net income to net cash provided by (used in) operating activities    
Net realized and unrealized (gains) losses (50,050) (120,268)
Net (gain) loss on held for sale of business (3,825) 1,175
Non-cash compensation expense 7,911 3,717
Amortization/accretion of premiums and discounts 1,017 2,134
Depreciation and amortization expense 17,714 18,261
Non-cash lease expense 6,508 6,520
Deferred provision (benefit) for income taxes 29,339 10,777
Amortization of deferred financing costs 1,081 1,176
Other 1,123 133
Changes in operating assets and liabilities:    
Mortgage loans originated for sale (1,942,612) (2,100,276)
Proceeds from the sale of mortgage loans originated for sale 2,195,612 2,184,852
(Increase) decrease in notes and accounts receivable 2,313 (57,859)
(Increase) decrease in reinsurance receivables (313,491) (99,190)
(Increase) decrease in deferred acquisition costs (105,826) (123,510)
(Increase) decrease in other assets 5,224 337
Increase (decrease) in unearned premiums 225,405 192,430
Increase (decrease) in policy liabilities and unpaid claims 181,221 80,176
Increase (decrease) in deferred revenue 93,625 112,062
Increase (decrease) in reinsurance payable 51,630 14,839
Increase (decrease) in other liabilities and accrued expenses (505) 15,518
Net cash provided by (used in) operating activities 400,857 186,039
Investing Activities:    
Purchases of investments (872,037) (1,251,741)
Proceeds from sales and maturities of investments 944,531 1,064,915
Purchases of property, plant and equipment (5,314) (2,103)
Proceeds from the sale of businesses and other assets 742 125
Proceeds from notes receivable 59,657 40,337
Issuance of notes receivable (83,761) (52,957)
Business and asset acquisitions, net of cash and deposits (14,960) 133
Net cash provided by (used in) investing activities 28,858 (201,291)
Financing Activities:    
Dividends paid (4,705) (4,020)
Cash received for the exercise of warrants 13,724 0
Net non-controlling interest (redemptions) contributions (5,081) (1,384)
Payment of WP Transaction costs (12,848) 0
Payment of debt issuance costs (6) (62)
Proceeds from borrowings and mortgage notes payable 2,114,394 2,265,796
Principal paydowns of borrowings and mortgage notes payable (2,409,398) (2,257,947)
Repurchases of common stock and other changes in additional paid-in capital (1,654) (2,882)
Net cash provided by (used in) financing activities (104,324) (499)
Effect of exchange rate changes on cash (6,833) 0
Net increase (decrease) in cash, cash equivalents and restricted cash 318,558 (15,751)
Cash, cash equivalents and restricted cash – beginning of period 195,086 195,275
Cash, cash equivalents and restricted cash – beginning of period - held for sale 9,360 4,879
Cash, cash equivalents and restricted cash – end of period 523,004 184,403
Less: Reclassification of cash to held for sale / deconsolidation of cash previously held for sale 9,172 12,319
Cash, cash equivalents and restricted cash – end of period 513,832 172,084
Supplemental Disclosure of Cash Flow Information:    
Right of use asset obtained in exchange for lease liability 12,232 3,046
Bonds and trade receivables exchanged for corporate loans and equity securities 19,846 0
Shares issued in exchange for vested subsidiary awards 659
Reconciliation of cash, cash equivalents and restricted cash    
Cash and cash equivalents 503,488  
Restricted cash 10,344  
Total cash, cash equivalents and restricted cash shown in the statements of cash flows 513,832 172,084
Fortegra Common Interest    
Financing Activities:    
Issuance of stock, noncontrolling interests 98,433 0
Fortegra preferred interests    
Financing Activities:    
Issuance of stock, noncontrolling interests 83,486 0
Fortegra Warrants    
Financing Activities:    
Issuance of warrants 13,101 0
Additional Warrants    
Financing Activities:    
Issuance of warrants $ 6,230 $ 0